B2-05: Frontline cytotoxic chemotherapy (CTx) for newly diagnosed non-small cell lung cancer (NSCLC) patients presenting with brain metastasis compared to whole brain radiotherapy (WBRT): Result of a randomized pilot study  by Lee, Dae Ho et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS338
four factors were compared to those with two or fewer. Pts with more 
than two risk factors had a signiﬁcantly shorter survival (276 v. 169 
days; HR= 1.93, p<0.0001). Outcome did not differ between single v. 
doublet therapy in lower risk pts (median survivals 271 v. 286 days, 
whereas higher risk pts showed a trend toward increased estimated 
median survival increased with doublet therapy (186 v. 148 days; HR= 
0.84, p=0.16). 
Conclusions: These data suggest that stratiﬁcation using these clinical 
factors may be appropriate in future trials. PS 2 patients deﬁned as 
higher risk by these factors may beneﬁt from more intensive therapy; in 
contrast, pts with two or fewer risk factors may not gain further clinical 
beneﬁt from more intensive therapy. 
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Background: WBRT followed by CTx is commonly used for NSCLC 
patients (pts) with brain metastasis. However, when neurologic symp-
toms or signs are absent or controlled by supportive care, CTx could 
be a choice of treatment. We conducted a randomized trial of frontline 
CTx compared with WBRT in this clinical setting whether frontline 
CTx was feasible and its efﬁcacy and toxicity proﬁle as well as quality 
of life and survival outcome was affected by the time of WBRT.
Methods: The eligibility criteria are as follows: pathologic conﬁrmed 
NSCLC, stage IV with brain metastasis at ﬁrst diagnosis, age 18-75, 
ECOG PS 0-2, and adequate organ functions. After stratiﬁed according 
to PS (ECOG 0-1 vs 2), the number of intracranial metastases (<3 vs 
3≤) and presence of extrathoracic extracranial metastasis, eligible pts 
were randomized to the two arms; Arm A, CTx followed by WBRT; 
Arm B, WBRT followed by CTx. CTx consisted of gemcitabine 900 
mg/m2 and vinorelbine 25 mg/m2 on D1 & 8 q 3 wk, up to 6 cycles. 
WBRT consisted of 30Gy/10fx/12d. We assessed tumor response, 
toxicity proﬁle and quality of life according to WHO response criteria, 
NCICTC and EORTC C-30/LC-13 questionaire, respectively.
Results: Between 2002 Aug and 2005 Nov, 48 pts were enrolled. All of 
25 pts in Arm A received CTx and WBRT, while 4 (17%) of 23 pts in 
Arm B could not receive CTx due to deterioration of PS or death dur-
ing or immediately after WBRT. Intracranial tumor responses to CTx 
in Arm A were closely correlated with extracranial responses (k=0.82). 
There were no statistically signiﬁcant differences in overall response 
rate (28% vs. 43%), time-to-progression (6.4 mo vs 6.3 mo) and 
survival (9.1 mo vs 9.9 mo). However, grade 3/4 neutropenia occurred 
more frequently in Arm B (79% vs 40%, p=0.014). Cognitive function 
deteriorated during frontline CTx, while it did not deteriorate during 
CTx after WBRT although the score already lowered after WBRT.
Conclusions: Frontline chemotherapy can be an appropriate treatment 
when neurologic symptoms or signs are absent or controlled by sup-
portive care. The timing and the real need for WBRT should be deﬁned 
in further trials.
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Background: Platinum and gemcitabine chemotherapy for NSCLC is 
usually administered with cisplatin or carboplatin on day 1 and gem-
citabine on days 1 and 8 of a 21 day cycle. Cisplatin administration is 
resource intensive for treatment facilities and nursing time due to ﬂuid 
hydration required to prevent nephrotoxicity. Carboplatin is conve-
niently administered over 30 minutes to 1 hour without ﬂuid hydration, 
is less nephrotoxic, neurotoxic and emetogenic, but haematological 
toxicity may be greater. A fractionated regimen of cisplatin 35mg/m2 
administered on days 1 and 8 of each cycle can be given without 
extended hydration regimens, may be less toxic, and of similar efﬁcacy. 
We conducted this multicentre, randomised, phase III trial to compare 
hospitalisation rates for treatment of toxicity between Gemcitabine 
1250mg/m2 iv and cisplatin 35mg/m2 iv day 1 and 8 (GCis) every 21 
days and Gemcitabine 1250mgs/m2 iv days 1 and 8 and carboplatin at a 
dosage of AUC 5 day 1(GCarbo) every 21 days, for a total of 4 cycles, 
in patients with NSCLC. 
Methods: Eligible patients had inoperable stage III or IV NSCLC, KPS 
greater than or equal to 50, and adequate organ function. Patients were 
stratiﬁed by disease stage and performance status. The primary endpoint 
was hospitalisation for treatment of toxicity. The study had 90% power to 
detect a reduction in extra overnight stays from 30 to 15% requiring 400 
patients. Secondary objectives included overall survival and toxicity.
Results: 400 patients were randomised between Nov 2002 and Aug 
2006. Currently 350 patients are evaluable for the primary objective. A 
total of 603 and 614 cycles were administered to patients on the GCis 
and GCarbo arms, respectively. The number of overnight stays required 
for chemotherapy administration did not differ with only ﬁve patients 
in the GCis arm and eight patients in the GCarbo arm, p=0.08. Other 
overnight stays were required by 51 (28%) patients who were treated 
with GCis and 68 (40%) patients who received GCarbo (p=0.04). There 
was no difference in the number of days of iv antibiotics adminis-
tered, p=0.41. There were signiﬁcantly more patients requiring blood 
and platelet transfusions in the GCarbo arm with 53% of patients 
requiring at least one blood transfusion (p=0.01) and 22% requiring 
platelets(p=0.002). Patients on GCis reported more nausea, p=0.04, and 
peripheral neuropathy, p=0.008 whereas patients on GCarbo reported 
more rash, p=0.008. The majority were grade 1 and 2 toxicities. There 
were no differences in vomiting, alopecia, mucositis, infection, renal 
toxicity, tinnitus, ﬂu like symptoms, oedema, deafness or ﬂushing. 
There was no difference in survival, median 9.1 and 9.5 months 
(p=0.41) with 1-year survival at 39% and 42% for GCis and GCarbo, 
respectively.
Conclusion: This preliminary analysis demonstrates that fractionated 
cisplatin treatment with gemcitabine can be given safely to an outpa-
tient and is well tolerated, with signiﬁcantly less requirement for blood 
and platelet transfusions, and similar survival outcome to that of the 
GCarbo regimen. An updated analysis will be available later this year.
